Selected research
Market Structure
Global Inhaled Corticosteroid Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Inhaled Corticosteroid market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Inhaled Corticosteroid is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Inhaled Corticosteroid is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Inhaled Corticosteroid is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Inhaled Corticosteroid is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Inhaled Corticosteroid include Teva Pharmaceutical, Sanofi, Johnson and Johnson, Novartis, Merck, Pfizer, GSK, Amgen and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Inhaled Corticosteroid market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Inhaled Corticosteroid and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Inhaled Corticosteroid sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Inhaled Corticosteroid market size, projected growth trends, production technologies, key applications, and end-use industries.
Inhaled Corticosteroid Segment by Company
Teva Pharmaceutical
Sanofi
Johnson and Johnson
Novartis
Merck
Pfizer
GSK
Amgen
AstraZeneca
Teijin
Sumitomo
Kos Pharmaceutical
Glaxo's Advair
Inhaled Corticosteroid Segment by Type
Mometasone
Fluticasone Inhaler Powder
Budesonide
Beclomethasone Dipropionate
Others
Inhaled Corticosteroid Segment by Application
Respiratory Care Centers
Hospitals
Clinics
Others
Inhaled Corticosteroid Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inhaled Corticosteroid market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inhaled Corticosteroid and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inhaled Corticosteroid.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Inhaled Corticosteroid market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Inhaled Corticosteroid manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Inhaled Corticosteroid in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Inhaled Corticosteroid in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Mometasone
- Fluticasone Inhaler Powder
- Budesonide
- Beclomethasone Dipropionate
- Others
Applications
- Respiratory Care Centers
- Hospitals
- Clinics
- Others
Companies covered
- Teva Pharmaceutical
- Sanofi
- Johnson and Johnson
- Novartis
- Merck
- Pfizer
- GSK
- Amgen
- AstraZeneca
- Teijin
- Sumitomo
- Kos Pharmaceutical
- Glaxo's Advair
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Inhaled Corticosteroid Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Inhaled Corticosteroid Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Inhaled Corticosteroid Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Inhaled Corticosteroid Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Inhaled Corticosteroid Market Dynamics
- 2.1 Inhaled Corticosteroid Industry Trends
- 2.2 Inhaled Corticosteroid Industry Drivers
- 2.3 Inhaled Corticosteroid Industry Opportunities and Challenges
- 2.4 Inhaled Corticosteroid Industry Restraints
3 Inhaled Corticosteroid Market by Manufacturers
- 3.1 Global Inhaled Corticosteroid Revenue by Manufacturers (2021-2026)
- 3.2 Global Inhaled Corticosteroid Sales by Manufacturers (2021-2026)
- 3.3 Global Inhaled Corticosteroid Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Inhaled Corticosteroid Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Inhaled Corticosteroid Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Inhaled Corticosteroid Manufacturers, Product Type & Application
- 3.7 Global Inhaled Corticosteroid Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Inhaled Corticosteroid Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Inhaled Corticosteroid Players Market Share by Revenue in 2025
- 3.8.3 2025 Inhaled Corticosteroid Tier 1, Tier 2, and Tier 3
4 Inhaled Corticosteroid Market by Type
- 4.1 Inhaled Corticosteroid Type Introduction
- 4.1.1 Mometasone
- 4.1.2 Fluticasone Inhaler Powder
- 4.1.3 Budesonide
- 4.1.4 Beclomethasone Dipropionate
- 4.1.5 Others
- 4.2 Global Inhaled Corticosteroid Sales by Type
- 4.2.1 Global Inhaled Corticosteroid Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Inhaled Corticosteroid Sales by Type (2021-2032)
- 4.2.3 Global Inhaled Corticosteroid Sales Market Share by Type (2021-2032)
- 4.3 Global Inhaled Corticosteroid Revenue by Type
- 4.3.1 Global Inhaled Corticosteroid Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Inhaled Corticosteroid Revenue by Type (2021-2032)
- 4.3.3 Global Inhaled Corticosteroid Revenue Market Share by Type (2021-2032)
5 Inhaled Corticosteroid Market by Application
- 5.1 Inhaled Corticosteroid Application Introduction
- 5.1.1 Respiratory Care Centers
- 5.1.2 Hospitals
- 5.1.3 Clinics
- 5.1.4 Others
- 5.2 Global Inhaled Corticosteroid Sales by Application
- 5.2.1 Global Inhaled Corticosteroid Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Inhaled Corticosteroid Sales by Application (2021-2032)
- 5.2.3 Global Inhaled Corticosteroid Sales Market Share by Application (2021-2032)
- 5.3 Global Inhaled Corticosteroid Revenue by Application
- 5.3.1 Global Inhaled Corticosteroid Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Inhaled Corticosteroid Revenue by Application (2021-2032)
- 5.3.3 Global Inhaled Corticosteroid Revenue Market Share by Application (2021-2032)
6 Global Inhaled Corticosteroid Sales by Region
- 6.1 Global Inhaled Corticosteroid Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Inhaled Corticosteroid Sales by Region (2021-2032)
- 6.2.1 Global Inhaled Corticosteroid Sales by Region (2021-2026)
- 6.2.2 Global Inhaled Corticosteroid Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Inhaled Corticosteroid Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Inhaled Corticosteroid Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Inhaled Corticosteroid Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Inhaled Corticosteroid Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Inhaled Corticosteroid Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Inhaled Corticosteroid Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Inhaled Corticosteroid Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Inhaled Corticosteroid Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Inhaled Corticosteroid Revenue by Region
- 7.1 Global Inhaled Corticosteroid Revenue by Region
- 7.1.1 Global Inhaled Corticosteroid Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Inhaled Corticosteroid Revenue by Region (2021-2026)
- 7.1.3 Global Inhaled Corticosteroid Revenue by Region (2027-2032)
- 7.1.4 Global Inhaled Corticosteroid Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Inhaled Corticosteroid Revenue (2021-2032)
- 7.2.2 North America Inhaled Corticosteroid Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Inhaled Corticosteroid Revenue (2021-2032)
- 7.3.2 Europe Inhaled Corticosteroid Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Inhaled Corticosteroid Revenue (2021-2032)
- 7.4.2 Asia-Pacific Inhaled Corticosteroid Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Inhaled Corticosteroid Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Inhaled Corticosteroid Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Teva Pharmaceutical
- 8.1.1 Teva Pharmaceutical Company Information
- 8.1.2 Teva Pharmaceutical Business Overview
- 8.1.3 Teva Pharmaceutical Inhaled Corticosteroid Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Teva Pharmaceutical Inhaled Corticosteroid Product Portfolio
- 8.1.5 Teva Pharmaceutical Recent Developments
- 8.2 Sanofi
- 8.2.1 Sanofi Company Information
- 8.2.2 Sanofi Business Overview
- 8.2.3 Sanofi Inhaled Corticosteroid Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Sanofi Inhaled Corticosteroid Product Portfolio
- 8.2.5 Sanofi Recent Developments
- 8.3 Johnson and Johnson
- 8.3.1 Johnson and Johnson Company Information
- 8.3.2 Johnson and Johnson Business Overview
- 8.3.3 Johnson and Johnson Inhaled Corticosteroid Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Johnson and Johnson Inhaled Corticosteroid Product Portfolio
- 8.3.5 Johnson and Johnson Recent Developments
- 8.4 Novartis
- 8.4.1 Novartis Company Information
- 8.4.2 Novartis Business Overview
- 8.4.3 Novartis Inhaled Corticosteroid Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Novartis Inhaled Corticosteroid Product Portfolio
- 8.4.5 Novartis Recent Developments
- 8.5 Merck
- 8.5.1 Merck Company Information
- 8.5.2 Merck Business Overview
- 8.5.3 Merck Inhaled Corticosteroid Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Merck Inhaled Corticosteroid Product Portfolio
- 8.5.5 Merck Recent Developments
- 8.6 Pfizer
- 8.6.1 Pfizer Company Information
- 8.6.2 Pfizer Business Overview
- 8.6.3 Pfizer Inhaled Corticosteroid Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Pfizer Inhaled Corticosteroid Product Portfolio
- 8.6.5 Pfizer Recent Developments
- 8.7 GSK
- 8.7.1 GSK Company Information
- 8.7.2 GSK Business Overview
- 8.7.3 GSK Inhaled Corticosteroid Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 GSK Inhaled Corticosteroid Product Portfolio
- 8.7.5 GSK Recent Developments
- 8.8 Amgen
- 8.8.1 Amgen Company Information
- 8.8.2 Amgen Business Overview
- 8.8.3 Amgen Inhaled Corticosteroid Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Amgen Inhaled Corticosteroid Product Portfolio
- 8.8.5 Amgen Recent Developments
- 8.9 AstraZeneca
- 8.9.1 AstraZeneca Company Information
- 8.9.2 AstraZeneca Business Overview
- 8.9.3 AstraZeneca Inhaled Corticosteroid Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 AstraZeneca Inhaled Corticosteroid Product Portfolio
- 8.9.5 AstraZeneca Recent Developments
- 8.10 Teijin
- 8.10.1 Teijin Company Information
- 8.10.2 Teijin Business Overview
- 8.10.3 Teijin Inhaled Corticosteroid Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Teijin Inhaled Corticosteroid Product Portfolio
- 8.10.5 Teijin Recent Developments
- 8.11 Sumitomo
- 8.11.1 Sumitomo Company Information
- 8.11.2 Sumitomo Business Overview
- 8.11.3 Sumitomo Inhaled Corticosteroid Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Sumitomo Inhaled Corticosteroid Product Portfolio
- 8.11.5 Sumitomo Recent Developments
- 8.12 Kos Pharmaceutical
- 8.12.1 Kos Pharmaceutical Company Information
- 8.12.2 Kos Pharmaceutical Business Overview
- 8.12.3 Kos Pharmaceutical Inhaled Corticosteroid Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Kos Pharmaceutical Inhaled Corticosteroid Product Portfolio
- 8.12.5 Kos Pharmaceutical Recent Developments
- 8.13 Glaxo's Advair
- 8.13.1 Glaxo's Advair Company Information
- 8.13.2 Glaxo's Advair Business Overview
- 8.13.3 Glaxo's Advair Inhaled Corticosteroid Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Glaxo's Advair Inhaled Corticosteroid Product Portfolio
- 8.13.5 Glaxo's Advair Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Inhaled Corticosteroid Value Chain Analysis
- 9.1.1 Inhaled Corticosteroid Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Inhaled Corticosteroid Production Mode & Process
- 9.2 Inhaled Corticosteroid Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Inhaled Corticosteroid Distributors
- 9.2.3 Inhaled Corticosteroid Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst